Diagnostic Use of Post-therapy I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2020 Sep 5

PMID 32887257

Citations 5

Authors

Hiroshi Wakabayashi

Daiki Kayano

Anri Inaki

Raita Araki

Rie Kuroda

Norihito Akatani

Takafumi Yamase

Satoru Watanabe

Tomo Hiromasa

Yuji Kunita

Hiroshi Mori

Shintaro Saito

Yasuhiro Ikawa

Toshihiro Fujiki

Seigo Kinuya

Affiliations

Soon will be listed here.

Abstract

I-meta-iodobenzylguanidine (I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy I-mIBG scintigraphy may detect more lesions compared with diagnostic I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy I-mIBG scintigraphy in children who received I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy I-mIBG scintigraphy was performed four days after injection. The post-therapy I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy I-mIBG scintigraphy can provide valuable information for detecting residual disease.

Citing Articles

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma - a narrative review.

Costa D, Goncalves-Nobre J, Sampaio-Alves M, Guerra N, Ribeiro J, Espiney Amaro C Front Oncol. 2023; 13:1254322.

PMID: 37823059 PMC: 10562625. DOI: 10.3389/fonc.2023.1254322.

Nonspecific Gastrointestinal Symptoms as the First Sign of Ganglioneuroblastoma Intermixed-Case Report and Literature Review.

Lipinski L, Lipinska J, Kowalczuk M, Kopec I, Wozniak M, Mitek-Palusinska J J Clin Med. 2023; 12(18).

PMID: 37763032 PMC: 10531539. DOI: 10.3390/jcm12186092.

[Radiological imaging of neuroblastoma].

Korber F, Schafer J Radiologe. 2021; 61(7):639-648.

PMID: 34156482 DOI: 10.1007/s00117-021-00875-7.

Theranostics in Oncology-Thriving, Now More than Ever.

Werner R, Higuchi T, Pomper M, Rowe S Diagnostics (Basel). 2021; 11(5).

PMID: 33946670 PMC: 8146294. DOI: 10.3390/diagnostics11050805.

Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma-A National Retrospective Study.

Ussowicz M, Wieczorek A, Dluzniewska A, Pieczonka A, Debski R, Drabko K Front Oncol. 2021; 11:647361.

PMID: 33912462 PMC: 8075349. DOI: 10.3389/fonc.2021.647361.

References

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M . Neuroblastoma. Jpn J Clin Oncol. 2018; 48(3):214-241. DOI: 10.1093/jjco/hyx176. View

Yang J, Codreanu I, Servaes S, Zhuang H . I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nucl Med Commun. 2012; 33(11):1134-7. DOI: 10.1097/MNM.0b013e3283570ffe. View

Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H . Draft guidelines regarding appropriate use of (131)I-MIBG radiotherapy for neuroendocrine tumors : Guideline Drafting Committee for Radiotherapy with (131)I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med. 2015; 29(6):543-52. DOI: 10.1007/s12149-015-0960-z. View

Parisi M, Eslamy H, Park J, Shulkin B, Yanik G . ¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. Semin Nucl Med. 2016; 46(3):184-202. DOI: 10.1053/j.semnuclmed.2016.02.002. View

Haas-Kogan D, Swift P, Selch M, Haase G, Seeger R, Gerbing R . Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003; 56(1):28-39. DOI: 10.1016/s0360-3016(02)04506-6. View

Pfluger T, Piccardo A . Neuroblastoma: MIBG Imaging and New Tracers. Semin Nucl Med. 2017; 47(2):143-157. DOI: 10.1053/j.semnuclmed.2016.10.007. View

Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T . Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol. 2018; 23(5):965-973. DOI: 10.1007/s10147-018-1281-8. View

Hickeson M, Charron M, Maris J, Brophy P, Kang T, Zhuang H . Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer. 2004; 42(3):268-74. DOI: 10.1002/pbc.10454. View

Mazloom A, Louis C, Nuchtern J, Kim E, Russell H, Allen-Rhoades W . Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014; 90(4):858-62. PMC: 5107988. DOI: 10.1016/j.ijrobp.2014.07.019. View

10.

Kayano D, Taki J, Fukuoka M, Wakabayashi H, Inaki A, Nakamura A . Low-dose (123)I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma. Nucl Med Commun. 2011; 32(10):941-6. DOI: 10.1097/MNM.0b013e32834a4445. View

11.

Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H . Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002; 29(12):1581-7. DOI: 10.1007/s00259-002-0973-4. View

12.

Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M . Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med. 1995; 22(10):1180-3. DOI: 10.1007/BF00800601. View

13.

Liu B, Zhuang H, Servaes S . Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors. Q J Nucl Med Mol Imaging. 2013; 57(1):21-8. View

14.

Lee J, Lee S, Cho H, Ma Y, Yoo K, Sung K . Incorporation of high-dose I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017; 10(1):108. PMC: 5432997. DOI: 10.1186/s13045-017-0477-0. View

15.

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G . EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008; 35(5):1039-47. DOI: 10.1007/s00259-008-0715-3. View

16.

Pai Panandiker A, McGregor L, Krasin M, Wu S, Xiong X, Merchant T . Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int J Radiat Oncol Biol Phys. 2009; 76(4):1161-5. PMC: 2884276. DOI: 10.1016/j.ijrobp.2009.03.068. View

17.

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris J . Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2011; 57(7):1124-9. DOI: 10.1002/pbc.23062. View

18.

Fukuoka M, Taki J, Mochizuki T, Kinuya S . Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 2010; 36(1):1-7. DOI: 10.1097/RLU.0b013e3181feeb5e. View

19.

Suh J, Koh K, Min S, Kim Y, Kim H, Im H . Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant. 2020; 24(2):e13658. DOI: 10.1111/petr.13658. View